The US is hooked on unregulated peptides. But are they effective, or even safe?
livescience - The world of peptides has exploded in wellness circles, but the benefits of injecting these gray-market molecules rest on little clinical evidence.
AI Summary: Unregulated peptide products have proliferated in the US, raising safety and efficacy concerns as federal regulators convene a contentious panel that includes proponents of these off‑label compounds. The debate highlights a market gap where hype often outpaces evidence — and where regulators must decide whether to tidy up the wild west or watch it fester.
Related Stories
The peptide problem: Hype outruns evidence, researchers caution / 1 month
FDA clears AstraZeneca’s new blood-pressure drug baxdrostat / 6 wks
FDA escalates push to withdraw Amgen’s Tavneos; Amgen updates label / 2 months
FDA links eight deaths to Amgen’s Tavneos; scrutiny intensifies / 3 months
Denali drug receives accelerated approval for rare CNS indication / 3 months
FDA launches individualized therapy framework for ultra-rare diseases / 4 months
FDA makes one pivotal trial the default for drug approvals / 4 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Novo Nordisk, Infectious Disease, Supplements, Cancer Research and look for the RSS link.
StackHealth Time Machine